SG11202104682PA - Cationic lipids containing silicon - Google Patents

Cationic lipids containing silicon

Info

Publication number
SG11202104682PA
SG11202104682PA SG11202104682PA SG11202104682PA SG11202104682PA SG 11202104682P A SG11202104682P A SG 11202104682PA SG 11202104682P A SG11202104682P A SG 11202104682PA SG 11202104682P A SG11202104682P A SG 11202104682PA SG 11202104682P A SG11202104682P A SG 11202104682PA
Authority
SG
Singapore
Prior art keywords
containing silicon
cationic lipids
lipids containing
cationic
silicon
Prior art date
Application number
SG11202104682PA
Inventor
Michael J Abrams
James Heyes
Richard J Holland
Kieu Mong Lam
Mark Wood
Original Assignee
Arbutus Biopharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arbutus Biopharma Corp filed Critical Arbutus Biopharma Corp
Publication of SG11202104682PA publication Critical patent/SG11202104682PA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/5123Organic compounds, e.g. fats, sugars
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/7105Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • C07F7/1872Preparation; Treatments not provided for in C07F7/20
    • C07F7/1888Preparation; Treatments not provided for in C07F7/20 by reactions involving the formation of other Si-linkages, e.g. Si-N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages
    • C07F7/1872Preparation; Treatments not provided for in C07F7/20
    • C07F7/1892Preparation; Treatments not provided for in C07F7/20 by reactions not provided for in C07F7/1876 - C07F7/1888
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111General methods applicable to biologically active non-coding nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/14Type of nucleic acid interfering N.A.
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/32Special delivery means, e.g. tissue-specific
SG11202104682PA 2018-11-09 2019-11-08 Cationic lipids containing silicon SG11202104682PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862758108P 2018-11-09 2018-11-09
PCT/US2019/060556 WO2020097520A1 (en) 2018-11-09 2019-11-08 Cationic lipids containing silicon

Publications (1)

Publication Number Publication Date
SG11202104682PA true SG11202104682PA (en) 2021-06-29

Family

ID=70612265

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104682PA SG11202104682PA (en) 2018-11-09 2019-11-08 Cationic lipids containing silicon

Country Status (13)

Country Link
US (1) US20220133636A1 (en)
EP (1) EP3877001A4 (en)
JP (1) JP2022501064A (en)
KR (1) KR20210105888A (en)
CN (1) CN113286622A (en)
AU (1) AU2019376006A1 (en)
BR (1) BR112021008953A2 (en)
CA (1) CA3119051A1 (en)
EA (1) EA202191315A1 (en)
IL (1) IL282957A (en)
MX (1) MX2021005462A (en)
SG (1) SG11202104682PA (en)
WO (1) WO2020097520A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021006539A2 (en) 2018-10-09 2021-07-06 Univ British Columbia compositions and competent systems of vesicles competent for transfection free of organic solvents and detergents and related methods
AU2020355000A1 (en) 2019-09-23 2022-03-17 Omega Therapeutics, Inc. Compositions and methods for modulating apolipoprotein B (APOB) gene expression
EP4041894A1 (en) 2019-09-23 2022-08-17 Omega Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATING HEPATOCYTE NUCLEAR FACTOR 4-ALPHA (HNF4a) GENE EXPRESSION
AU2021234302A1 (en) 2020-03-11 2022-11-10 Omega Therapeutics, Inc. Compositions and methods for modulating forkhead box p3 (foxp3) gene expression
WO2023283359A2 (en) 2021-07-07 2023-01-12 Omega Therapeutics, Inc. Compositions and methods for modulating secreted frizzled receptor protein 1 (sfrp1) gene expression

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070292688A1 (en) * 2005-08-18 2007-12-20 Eastman Kodak Company Silylamine modified nanoparticulate carriers
AU2009303345B2 (en) * 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
US9028603B2 (en) * 2011-06-09 2015-05-12 The Research Foundation Of State University Of New York Anti-fouling coating compositions and methods for preventing the fouling of surfaces
JP6590802B2 (en) * 2013-11-06 2019-10-16 ザ ユニバーシティ オブ シカゴThe University Of Chicago Nanoscale transporter for delivery or co-delivery of chemotherapeutic drugs, nucleic acids and photosensitizers
CN106834355B (en) * 2015-12-07 2021-02-23 北京大学 Cationic composite lipid nanodisk, and preparation method and application thereof
EP3269785A1 (en) * 2016-07-13 2018-01-17 Nitrochemie Aschau GmbH Composition for silicone rubber masses
WO2018119115A1 (en) * 2016-12-21 2018-06-28 Protiva Biotherapeutics, Inc. Methods for ameliorating infusion reactions
WO2019051257A2 (en) * 2017-09-11 2019-03-14 Arbutus Biopharma Corporation Methods for treating hepatitis b infections
US20220168222A1 (en) * 2019-04-26 2022-06-02 Genevant Sciences Gmbh Lipid nanoparticles

Also Published As

Publication number Publication date
BR112021008953A2 (en) 2021-08-10
CA3119051A1 (en) 2020-05-14
US20220133636A1 (en) 2022-05-05
KR20210105888A (en) 2021-08-27
MX2021005462A (en) 2021-08-24
JP2022501064A (en) 2022-01-06
EA202191315A1 (en) 2021-09-08
EP3877001A1 (en) 2021-09-15
AU2019376006A1 (en) 2021-06-03
IL282957A (en) 2021-06-30
CN113286622A (en) 2021-08-20
WO2020097520A1 (en) 2020-05-14
EP3877001A4 (en) 2022-08-17

Similar Documents

Publication Publication Date Title
IL281948A (en) Ionizable amine lipids
IL278864A (en) Shared antigens
IL283622A (en) Modified amine lipids
IL282957A (en) Cationic lipids containing silicon
ZAA201801488S (en) Packages
EP3481897C0 (en) Silicone hydrogels comprising polyamides
IL262574B (en) Cationic lipid
CA186279S (en) Packaging
EP3252043A4 (en) Cationic lipid
IL275617B1 (en) Cationic lipids
ZAA201801502S (en) Packages
IL280620A (en) Cationic lipid
EP3733647A4 (en) Cationic lipid
CA186880S (en) Packaging
AU201615981S (en) Mascara Package
CA186278S (en) Packaging
SG10201805356XA (en) Package structure
PL3404073T3 (en) Hydrophilic isocyanurates containing aloxysilane
GB201818490D0 (en) Secure packaging
EP3521270A4 (en) Cationic lipid compound
EP3873818C0 (en) Package
CA194729S (en) Packaging
PT3623307T (en) Packaging
GB201814338D0 (en) Packaging four
ZAA201801687S (en) Packaging